Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
muscular dystrophy
Biotech
Edgewise drug lowers biomarker in ph. 2 muscular dystrophy trial
Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a phase 2 trial.
James Waldron
Dec 16, 2024 7:40am
DMD gene therapy uses cells to stitch together mRNA in mice
Nov 14, 2024 3:10pm
Avidity therapy shows possible benefit in muscular dystrophy
Jun 12, 2024 7:00am
Sanofi pays Fulcrum $80M for rights to phase 3 rare disease drug
May 13, 2024 7:09am
PepGen gains a little pep in its step as FDA clears trial hold
Oct 12, 2023 7:00am
Sanofi wagers $400M in biobucks to go after muscular dystrophy
Oct 4, 2022 8:00am
